

DAFTAR PUSTAKA

1. El-Azizi M, Farag N, Khardori N. Antifungal activity of amphotericin B and voriconazole against the biofilms and biofilm-dispersed cells of *Candida albicans* employing a newly developed in vitro pharmacokinetic model. *Ann Clin Microbiol Antimicrob*. 2015;14(1):1–9.
2. Wahyuningsih R, Mulyati, Susilo J. Kandidosis . Dalam: Staf Pengajar Departemen FK UI, ed. Parasitologi kedokteran Edisi Keempat. Jakarta: Badan Penerbit FK UI, 2008;356.
3. Brooks GF, Carrol KC, Butel JS, Morse SA. Parasitologi Kedokteran. Jawetz Melnick & Adelberg's Mikrobiologi Kedokteran. 27. Jakarta EGC.
4. Kadek SJN, Jirna IN. Isolasi *Candida albicans* Dari Swab Mukosa Mulut Penderita Diabetes Melitus Tipe 2. *J Teknol Lab*. 2018;7(1):1.
5. Indira P, Kumar PM, Shalini S, Vaman K. Opportunistic Infections among People Living with HIV (PLHIV) with Diabetes Mellitus (DM) Attending a Tertiary Care Hospital in Coastal City of South India. 2015;245:4–11.
6. Arfiputri DS, Hidayati AN, Handayani S, Ervianti E. Risk factors of vulvovaginal candidiasis in dermatovenereology outpatients clinic of soetomo general hospital, Surabaya, Indonesia. *African J Infect Dis*. 2018;12(1):90–4.
7. Kalista KF, Chen LK, Wahyuningsih R. Karakteristik Klinis dan Prevalensi Pasien Kandidiasis Invasif di Rumah Sakit Cipto Mangunkusumo Clinical Characteristic and Prevalence of Invasive Candidiasis Patient in Cipto Mangunkusumo Hospital. *J Penyakit Dalam Indones [Internet]*. 2017;4(2):56–61.
8. Litt JZ. *Litt's Drug Eruption Reference Manual*. 11th edition. London: Taylor & Francis. 2005.
9. Tavallaee M, Rad MM. Fixed drug eruption resulting from fluconazole use: a case report. *J Med Case Rep [Internet]*. 2009;3(1):7368. Diunduh dari <http://www.jmedicalcasereports.com/content/3/1/7368>
10. Leite JGG, Brito ÉHS, Cordeiro RA, Brilhante RSN, Sidrim JJC, Bertini LM, et al. Chemical composition, toxicity and larvicidal and antifungal activities of *Persea americana* (avocado) seed extracts. *Rev Soc Bras Med Trop*. 2009;42(2):110–3.

11. Noble SM, Gianetti BA, Witchley JN. *Candida albicans* cell-type switching and functional plasticity in the mammalian host. *Nat Rev Microbiol*. 2017;15(2):96–108.
12. Lo L, Kadosh D, Carlisle PL, Banerjee M, Lazzell A, Monteagudo C. Expression levels of a filament-specific transcriptional regulator are sufficient to determine *Candida albicans* morphology and virulence. 2009;106(2).
13. Whiteway M, Bachewich C. *Morphogenesis in Candida*. 2007.
14. Ñ AL, Cabezo V. Analysis of *Candida albicans* plasma membrane proteome. 2009;4770–86.
15. Sheth CC, Johnson E, Baker ME, Haynes KEN, Mu FA. Phenotypic identification of *Candida albicans* by growth on chocolate agar. 2005;(December):735–8.
16. Biswas SK, Chaffin WL. Anaerobic Growth of *Candida albicans* Does Not Support Biofilm Formation Under Similar Conditions Used for Aerobic Biofilm. 2005;51:100–4.
17. Kibbler CC, Barton R, Gow NA, Howell s, MacCallum DM, Manuel RJ. *Oxford Textbook of Medical Mycology*. 1th ed. London: Oxford University Press, 2018: 11-3
18. Elorza MV, Valent E. Molecular organization of the cell wall of *Candida albicans* and its relation to pathogenicity. 2006;6:14–29.
19. Infeksi M. Mekanisme infeksi. 2004;(30):304–13.
20. Jacobsen ID, Hube B, Jacobsen ID, Hube B. Expert Review of Anti-infective Therapy *Candida albicans* morphology : still in focus. *Expert Rev Anti Infect Ther*. 2017;15(4):327–30.
21. Mukherjee PK, Zhou G, Munyon R, Ghannoum MA. *Candida* biofilm : a well-designed protected environment. 2005;(May):191–208.
22. Nobile CJ, Johnson AD. *Candida albicans* Biofilms and Human Disease. HHS Public Access. 2016;71–92.
23. Kaushik N, Pujalte GGA, Reese ST. Superficial Fungal Infections. *Prim Care - Clin Off Pract*. 2015;42(4):501–16.

24. Kauffman CA, Pappas PG, Sobel JD, Dismukes WE. Essentials of Clinical Mycology. 2th eds. London: Springer; 2011: 168
25. Hamidah, Ambarwati, Peni, I. Isolasi dan identifikasi isolat actinomycetes dari rizosfer padi (*Oryza sativa* L.) Sebagai Penghasil Antifungi. Naskah Publikasi. 2013: 1–15.
26. Campoy S, Adrio JL. Antifungals. *Biochem Pharmacol*. 2017; 133: 86-96.
27. Akins RA. An update on antifungal targets and mechanisms of resistance in *Candida albicans*. 2005;(Juni):285–318.
28. Hiraakawa MP, Martinez DA, Sakthikumar S, Anderson MZ, Berlin A, Gujja S, et al. Genetic and phenotypic intra-species variation in *Candida albicans*. 2015;413–25.
29. Ranade SS, Thiagarajan P. A Review on *Persea Americana* Mill . (Avocado) - Its Fruit and Oil. 2015;8(6):72–7.
30. Tim Trubus. 100 Plus Herbal Indonesia Bukti Ilmiah dan Racikan Vol.11, Penerbit PT. Trubus Swadaya, Depok.2013
31. Yuniarti, T, Ensiklopedia Tanaman Obat Tradisional, Cetakan Pertama MedPress, Yogyakarta.2008
32. Noorul H, Nesar A, Zafar K, Khalid M, Zeeshan A, Vartika S. Health benefits and pharmacology of *Persea americana* mill. (Avocado) International Journal of Research in Health benefits and pharmacology of *Persea americana* mill . (Avocado). 2016;(April).
33. Seleem D, Pardi V, Mendonça R. Archives of Oral Biology Review of flavonoids: A diverse group of natural compounds with anti- *Candida albicans* activity in vitro. *Arch Oral Biol*. 2017;76:76–83.
34. Alves A, Filho DO, Mara H, Fernandes B, Sousa JP De. In vitro anti-*Candida* activity and mechanism of action of the flavonoid isolated from *Praxelis clematidea* against *Candida albicans* species. 2016;6(01):66–9.
35. Heinrich M, Barnes J, Gibbons S, Williamson EM. Farmakognosi dan Fitoterapi Jakarta: EGC; 2009: 82-105.

36. Khan H, Mubarak MS, Amin S. Antifungal Potential of Alkaloids As An Emerging Therapeutic Target Current Drug Targets. 2017; 18(16): 1825-35
37. Babbar N. An introduction to alkaloids and their applications in pharmaceutical chemistry. 2015;4(10):74–5.
38. Yang L, Liu X, Zhuang X, Feng X, Zhong L, Ma T. Antifungal Effects of Saponin Extract from Rhizomes of *Dioscorea panthaica* Prain et Burk against *Candida albicans*. Hindawi. 2018;2018.
39. Ashok P, Upadhyaya K. Tannins are Astringent. J Pharmacogn Phytochem. 2012;1(3):45–50. Diunduh dari http://www.phytojournal.com/vol1Issue3/Issue_sept_2012/8.1.pdf
40. Huang Q, Liu X, Zhao G, Hu T, Wang Y. Potential and challenges of tannins as an alternative to in-feed antibiotics for farm animal production. Anim Nutr [Internet]. 2018;4(2):137–50.
41. Syamsyuni HA. Ilmu Resep. Jakarta: EGC;2007:
42. Suurbaar J, Mosobil R, Donkor AM. Antibacterial and antifungal activities and phytochemical profile of leaf extract from different extractants of *Ricinus communis* against selected pathogens. BMC Res Notes. 2017;1–6.
43. Harmita, Radji M. Analisis Hayati. 3th eds. Jakarta: EGC; 2008: 2-5
44. Yongabi KA, Mbacham WF, Nubia KK, Singh RM, Box PO. Yeast strains isolated from HIV-seropositive patients in Cameroon and their sensitivity to extracts of eight medicinal plants. 2009;3(4):133–6.
45. Omokhua AG. Phytochemical and pharmacological investigations of invasive *Chromolaena odorata* (L.) R.M. King & H. Rob. (Asteraceae). Pietermaritzburg. 2015.
46. Eleanore Y. Analisis Fitokimia dan Aktivitas Antioksidan Ekstrak Daun Sengon (*Paraserianthes falcataria* (L) Nielsen) Menggunakan Metode DPPH. Skripsi. Departemen Biokimia Fakultas Matematika dan Ilmu Pengetahuan Alam Institut Pertanian Bogor. Bogor. 2013.
47. Paudel B, Bhattarai HD, Kim IC, Lee H, Sofronov R, Ivanova L, et al. Estimation of antioxidant, antimicrobial activity and brine shrimp toxicity of plants collected from Oymyakon region of the Republic of Sakha (Yakutia), Russia. 2014;1–6.

48. Gofar A. Uji efektivitas antijamur dari ekstrak daun ketepeng cina (*Cassia alata* L.) terhadap *Trichopyton mentagrophytes* secara *in vitro*. FK Unsri.Palembang: 2010.
49. Pfaller MA, Diekema DJ, Sheehan DJ. Interpretive Breakpoints for Fluconazole and *Candida* Revisited : a Blueprint for the Future of Antifungal Susceptibility Testing. 2006;19(2):435–47.
50. Astuti OR. Uji daya hambat ekstrak etanol daun sirih merah (*piper crocatum* & *pav*) terhadap *Candida albicans* ATCC 10231 secara *in vitro*. Skripsi Fakultas Kedokteran Universitas Muhammadiyah Surakarta. Surakarta: 2012.